Problems of antiarthritic therapy in the elderly

Area of Science:

• Gerontology
• Rheumatology
• Clinical Pharmacology

Background:

• Rheumatic diseases significantly impact the elderly, often leading to reduced mobility and extensive medication use.
• Antirheumatic drug use is common in older adults, necessitating a review of associated risks.
• Understanding drug-specific hazards is crucial for managing rheumatic conditions in this demographic.

Purpose of the Study:

• To review the potential hazards of antirheumatic drug use in the elderly population.
• To identify specific adverse effects associated with common analgesics, anti-inflammatory drugs, and disease-modifying antirheumatic drugs (DMARDs) in older individuals.
• To provide guidance on the safe and effective use of these medications in geriatric patients.

Main Methods:

• Literature review of antirheumatic drug use in the elderly.
• Analysis of reported adverse events and contraindications for various drug classes.
• Evaluation of drug efficacy and toxicity profiles in older adults compared to younger populations.

Main Results:

• Propoxyphene and acetaminophen carry risks of respiratory depression and reduced renal clearance, respectively.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause fluid retention, congestive heart failure, and deafness (salicylates). Phenylbutazone is contraindicated due to blood dyscrasia risk.
• Indomethacin may interfere with beta-blockers; chloroquine use increases retinal damage risk in the elderly.
• Injectable gold compounds and penicillamine are effective but may cause increased skin rashes and taste disturbances in older patients.
• Corticosteroids should be used judiciously for acute, severe conditions; gout treatment depends on renal function.

Conclusions:

• The elderly population experiences unique risks with antirheumatic drug use, requiring careful consideration of drug selection and monitoring.
• While some drugs like gold compounds remain effective, others like phenylbutazone should be avoided.
• Individualized treatment plans and vigilant monitoring are essential for optimizing outcomes and minimizing adverse events in elderly patients with rheumatic diseases.